Trial Profile
A study to evaluate the efficacy of Eribulin retreatment in HER2 negative Metastatic Breast Cancer patients - Phase II study -
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 May 2017
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 03 May 2017 New trial record